A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase IIα by Substituted Purine Analogs

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Pharmacology

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/mol.106.026856PMID 16880287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.

  2005cited by this paper
• Combining Etoposide and Dexrazoxane Synergizes with Radiotherapy and Improves Survival in Mice with Central Nervous System Tumors

  2005cited by this paper
• Biochemical and Proteomics Approaches to Characterize Topoisomerase IIα Cysteines and DNA as Targets Responsible for Cisplatin-Induced Inhibition of Topoisomerase IIα

  2005cited by this paper
• Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II

  2005cited by this paper
• Cobalt enhances DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells.

  2004cited by this paper
• DNA Topoisomerase II Is Required at the Time of Mitosis in Yeast

  2004cited by this paper
• Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα

  2003cited by this paper
• Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187

  2003cited by this paper
• Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.

  2003cited by this paper
• DNA Damage-mediated Apoptosis Induced by Selenium Compounds*

  2003cited by this paper
• Catalytic topoisomerase II inhibitors in cancer therapy.

  2003cited by this paper
• Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193

  2003influential reference
• Erratum: Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 (Proceedings of the National Academy of Sciences of the United States of America (September 16, 2003) 100:19 (10629-10634))

  2003cited by this paper
• Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition.

  2002cited by this paper
• Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF‐187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase IIα

  2002cited by this paper
• Catalytic inhibitors of topoisomerase II are DNA‐damaging agents: induction of chromosomal damage by merbarone and ICRF‐187

  2002cited by this paper
• Cellular roles of DNA topoisomerases: a molecular perspective

  2002cited by this paper
• Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells

  2001influential reference
• Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.

  2001cited by this paper
• Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation.

  2001cited by this paper
• Use of a real-time, coupled assay to measure the ATPase activity of DNA topoisomerase II.

  2001cited by this paper
• Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

  2001cited by this paper
• Steady-state and Rapid Kinetic Analysis of Topoisomerase II Trapped as the Closed-clamp Intermediate by ICRF-193*

  2000cited by this paper
• DNA topoisomerase IIβ and neural development

  2000cited by this paper
• Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.

  1998cited by this paper
• Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.

  1998cited by this paper
• Catalytic inhibitors of DNA topoisomerase II.

  1998cited by this paper
• DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.

  1997cited by this paper
• Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.

  1996cited by this paper
• Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

  1994cited by this paper
• Comparative molecular field analysis of CCK-B antagonists

  1994cited by this paper
• Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

  1993cited by this paper
• Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16).

  1993cited by this paper
• A model for tumor cell killing by topoisomerase poisons.

  1990cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper
• DNA topoisomerase II is required at the time of mitosis in yeast.

  1985cited by this paper
• Alkaline elution analysis, a new approach to the study of DNA single-strand interruptions in cells.

  1973cited by this paper

• Copper Catalyzed Three-Component Ullmann C-S Coupling in PEG for the Synthesis of 6-Aryl/alkylthio-purines.

  2024cites this paper
• Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα.

  2020cites this paper
• Substituted 4,5′-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIα

  2020cites this paper
• www.3d-qsar.com: a web portal that brings 3-D QSAR to all electronic devices—the Py-CoMFA web application as tool to build models from pre-aligned datasets

  2019cites this paper
• Gold Complexes for Therapeutic Purposes: an Updated Patent Review (2010-2015).

  2016cites this paper
• Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90

  2016cites this paper
• Discovery of Mono‐ and Disubstituted 1H‐Pyrazolo[3,4]pyrimidines and 9H‐Purines as Catalytic Inhibitors of Human DNA Topoisomerase IIα

  2015cites this paper
• 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.

  2015cites this paper
• Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIα.

  2014cites this paper
• Tandem deprotection-dimerization-macrocyclization route to C(2) symmetric cyclo-tetrapeptides.

  2014cites this paper
• Conformationally assisted lactamizations for the synthesis of symmetrical and unsymmetrical bis-2,5-diketopiperazines.

  2013cites this paper
• Application of 2,6-diazidopurine derivatives in the synthesis of thiopurine nucleosides

  2013cites this paper
• Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.

  2013cites this paper
• DNA catenation maintains structure of human metaphase chromosomes

  2012cites this paper
• Mitotic chromosomes are constrained by topoisomerase II–sensitive DNA entanglements

  2010cites this paper
• Comparison Data Sets for Benchmarking QSAR Methodologies in Lead Optimization

  2009cites this paper
• Partial Charge Calculation Method Affects CoMFA QSAR Prediction Accuracy

  2009cites this paper
• Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

  2009cites this paper
• The effect of molecular fields, lattice spacing and analysis options on CoMFA predictive ability

  2009cites this paper
• A Three-Dimensional Quantitative Structure-Activity Analysis of a New Class of Bisphenol Topoisomerase IIα Inhibitors

  2008cites this paper
• Whither combine? New opportunities for receptor-based QSAR.

  2007cites this paper